INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Design, Synthesis, And Biological Evaluation of CHIR-090 Analogs as Potential LPXC Inhibitors: A Comprehensive Review

Taukir Ansari[1]*, Rajat Choudhary[2], Ravi Kant Kushwaha[3], Sugat Shukla[4]

Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow Uttar Pradesh 226013

ARTICLE INFO

Published: 25 Jun. 2026
Keywords:
LpxC, Design, CHIR-090, Biological Evaluation, antimicrobial resistance
DOI:
10.5281/zenodo.20842250

ABSTRACT

The escalating global threat of multi-drug resistant (MDR) Gram-negative bacteria has necessitated the exploration of novel biochemical targets. To enable the development of novel LpxC inhibitors with potent antibacterial activities, several series of compounds were designed and synthesized and their antibacterial activities were evaluated. Among these, the zinc-dependent metalloenzyme UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) is highly prioritized. LpxC catalyzes the first committed and rate-limiting step in LPS biosynthesis—the deacetylation of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine. Because this pathway is absent in humans and essential for Gram-negative survival, LpxC inhibition represents a "silver bullet" potential for broad-spectrum activity. LpxC catalyzes the first committed step in the biosynthesis of Lipid A, the hydrophobic anchor of lipopolysaccharide (LPS), which is essential for the outer membrane integrity and viability of most Gram-negative pathogens. CHIR-090, a potent hydroxamic acid-based inhibitor, emerged as a seminal lead compound with nanomolar potency; however, its clinical progression was hindered by pharmacokinetic limitations and potential toxicity. This review provides an in-depth analysis of the design strategies, synthetic methodologies, and biological evaluations of CHIR-090 analogs. We examine the Structure-Activity Relationship (SAR) focused on modifying the hydroxamate head group, the scaffold backbones, and the hydrophobic tails to enhance metabolic stability and broaden the spectrum of activity against pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii.

INTRODUCTION

The rise of antimicrobial resistance (AMR) represents one of the most significant challenges to modern medicine. The "ESKAPE" pathogens—specifically the Gram-negative members *Klebsiella pneumoniae*, *Acinetobacter baumannii*,

***Corresponding Author:** Taukir Ansari
Address: *Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow Uttar Pradesh 226013*
Email : ataukir977@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Pseudomonas aeruginosa, and *Enterobacter* species—are increasingly resistant to "last-resort" carbapenems and polymyxins [1]. Unlike Gram-positive bacteria, Gram-negative bacteria possess a distinct outer membrane (OM) comprising a phospholipid inner leaflet and a lipopolysaccharide (LPS) outer leaflet. This asymmetric bilayer acts as a formidable permeability barrier against many hydrophobic drugs [2].

Lipid A is the essential component of LPS that anchors it to the OM. Its biosynthesis pathway, known as the Raetz pathway, involves nine conserved enzymes [3-4]. Among these, LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) is particularly attractive as an antibiotic target because it catalyzes the first irreversible step, has no mammalian homolog, and is highly conserved across virtually all Gram-negative species [5-6].

Historically, several classes of LpxC inhibitors have been developed, ranging from early sulfonamides to complex peptidic structures. However, the discovery of CHIR-090 by Chiron Corporation marked a turning point in the field, demonstrating that small-molecule hydroxamates could achieve potent, broad-spectrum antibacterial activity [6-7]. This paper reviews the evolution of CHIR-090 analogs, exploring how medicinal chemistry has navigated the balance between potency, safety, and pharmacokinetic viability.



Fig: Illustrative structures of CHIR-090 analogs as potential LpxC inhibitors

LpxC: Structure and Mechanism of Action

LpxC is a Zn^{2+}-dependent deacetylase. The enzyme structure typically features a unique "β-α-β" sandwich fold. The active site contains a single zinc ion coordinated by two histidines and one aspartic acid residue (His79, His238, and Asp242 in *E. coli*) [8]. The catalytic mechanism involves the polarization of a water molecule by the zinc ion, which then performs a nucleophilic attack on the amide carbonyl of the substrate, UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine [9-10].

Effective inhibitors of LpxC generally consist of three pharmacophoric elements:

1. **A Zinc-Binding Group (ZBG):** Usually a hydroxamic acid that chelates the Zn^{2+} ion in a bidentate fashion.[11]
2. **A Polar Scaffold:** That mimics the sugar-phosphate backbone of the natural substrate.

3. **A Hydrophobic Tail:** That occupies the "tunnel" or hydrophobic pocket of the enzyme, mimicking the myristoyl chain [12].

CHIR-090: The Lead Compound

CHIR-090 is a synthetic hydroxamic acid possessing an L-threonine-derived scaffold and a diphenylacetylene hydrophobic tail. It exhibits sub-nanomolar values against *E. coli* LpxC and shows Minimum Inhibitory Concentrations (MICs) comparable to ciprofloxacin against many isolates [13].

Despite its potency, CHIR-090 faced hurdles:

1. **Poor Solubility:** The highly hydrophobic tail leads to low aqueous solubility.
2. **Toxicity Concerns:** Hydroxamates are often associated with off-target inhibition of human matrix metalloproteinases (MMPs) and histone deacetylases (HDACs).[14]
3. **Cardiovascular Issues:** Early studies indicated potential hERG inhibition or blood pressure fluctuations in animal models [15].

These challenges spurred the design of analogs aimed at optimizing the "drug-likeness" of the CHIR-090 scaffold.

Design Strategies for CHIR-090 Analogs

A. Modifications of the Zinc-Binding Group (ZBG)

While the hydroxamate group is the most potent ZBG for LpxC, it is metabolically labile (susceptible to glucuronidation and hydrolysis) and potentially toxic. Researchers have explored bioisosteres such as:[16]

1. **Reverse hydroxamates:** To alter the orientation of chelation.
2. **N-methyl hydroxamates:** To reduce glucuronidation.
3. **Carboxylic acids and Phosphonates:** These generally show significantly reduced potency compared to hydroxamates due to weaker zinc affinity [17].
4. **Oxadiazolone and Thiadiazolone rings:** Designed to act as "masked" hydroxamates or stable mimics [18].

B. Scaffold Optimization

The L-threonine moiety in CHIR-090 provides the spatial orientation for the ZBG and the tail. Analogs have explored:[19]

1. **Cyclic Scaffolds:** Replacing the acyclic threonine with proline or morpholine derivatives to constrain the conformation and reduce the entropic penalty upon binding [20].
2. **Isoxazoline and Oxazoline Rings:** These heterocycles serve as rigid spacers that can mimic the peptide bond while improving metabolic stability [21].

C. Hydrophobic Tail Engineering

The diphenylacetylene tail of CHIR-090 is critical for potency but contributes to poor physical properties. Strategies include:

1. **Incorporation of Heterocycles:** Replacing one of the phenyl rings with pyridyl, pyrazolyl, or piperazinyl groups to increase polarity and solubility [22].
2. **Length Adjustment:** Shortening or lengthening the alkyne spacer to better fit the specific hydrophobic tunnels of *P. aeruginosa* versus *E. coli* [23].

Synthetic Methodologies

The synthesis of CHIR-090 analogs usually involves convergent pathways. A representative synthetic route involves:[24]

1. **Preparation of the Scaffold:** Starting from protected amino acids (e.g., Boc-L-Threonine).
2. **Introduction of the Tail:** This often utilizes the Sonogashira Coupling reaction. A terminal alkyne on the scaffold side is reacted with an aryl halide (or vice versa) using a Pd(0) catalyst and CuI [25].
3. **Formation of the Hydroxamic Acid:** The carboxylic acid precursor is activated (using EDC/HOBt or HATU) and reacted with hydroxylamine (NH_2OH) or a protected form (like O-THP-hydroxylamine) followed by deprotection [26].

Recent advances in synthesis include the use of Click Chemistry (azide-alkyne cycloaddition) to create triazole-linked tails, which offers higher yields and easier purification than traditional coupling methods [27].

Biological Evaluation

A. In Vitro Enzyme Inhibition

Analogs are first screened for their ability to inhibit recombinant LpxC enzymes. CHIR-090 typically yields an IC_{50} in the range of 1–5 nM. Effective analogs must maintain IC_{50} values below 50 nM to be considered viable antibacterial candidates [20]. Comparison against human HDACs and MMPs is essential to ensure selectivity [28].

B. Antibacterial Activity (MIC)

The Minimum Inhibitory Concentration (MIC) is the standard measure of potency. Most CHIR-090 analogs are tested against a panel of Gram-negative bacteria:

C. Wild-type E. coli: Serves as the primary benchmark.

D. P. aeruginosa (PAO1):

A difficult-to-treat pathogen due to robust efflux pumps (e.g., MexAB-OprM).

E. baumannii:

Often requires higher concentrations due to its low outer membrane permeability [29].

F. Mechanism of Resistance and Efflux

A significant finding in the biological evaluation of CHIR-090 analogs is the role of efflux pumps. Analogs with increased hydrophobicity are often substrates for the MexAB-OprM system in *Pseudomonas*. Consequently, the development of analogs often involves adding polar groups to bypass these pumps [30].

Key Analog Progressions: Case Studies

A. ACHN-975 and Related Compounds

Achaogen developed several LpxC inhibitors based on the hydroxamate-alkyne scaffold. ACHN-975 was the first LpxC inhibitor to enter clinical trials. It demonstrated potent activity against *P. aeruginosa* and *E. coli* but was discontinued after Phase I due to local inflammation at the injection site and limited systemic exposure [31].

B. LPC-011 and LPC-058

Developed by the Pei and Raetz groups, these analogs replaced the diphenylacetylene tail with more soluble variants. LPC-011, featuring a methyl group on the nitrogen and a specific tail modification, showed excellent activity against a broad range of pathogens and improved stability against hydrolysis [32].

C. PF-04753299 (Pfizer)

Pfizer explored analogs that incorporated a pyridone ring into the scaffold. This modification aimed to balance the lipophilicity and improve the

safety profile regarding hERG inhibition. While potent, issues regarding the "hydroxamate liability" (metabolism and toxicity) remained a concern [33].

Challenges and Future Perspectives

The primary challenge in LpxC inhibitor development remains the Hydroxamate Dilemma. While the hydroxamic acid is essential for potency, its metabolic instability and potential for metal-ion sequestration in the host are significant drawbacks.[34]

Future directions include:

1. **Non-Hydroxamate Inhibitors:** Finding ZBGs that can match the affinity of hydroxamates without the associated toxicity. Some success has been seen with N-hydroxy-formamides and specific imidazole-based structures [35].
2. **Siderophore Conjugation:** Attaching LpxC inhibitors to siderophore mimics to hijack the bacterial iron-uptake system, effectively "Trojan-horsing" the drug into the cell [36].
3. **Combination Therapy:** Using LpxC inhibitors at sub-MIC levels to sensitize bacteria to traditional antibiotics (like vancomycin or carbapenems) by compromising the outer membrane integrity [37].

CONCLUSION

LpxC remains one of the most promising yet elusive targets in antibiotic discovery. CHIR-090 provided a definitive proof-of-concept for the inhibition of Lipid A biosynthesis, demonstrating that targeting the membrane construction can lead to potent bactericidal effects. The development of CHIR-090 analogs has significantly advanced our understanding of the LpxC active site and the structural requirements for crossing the Gram-negative cell envelope. While clinical success has been limited by the pharmacokinetic properties of hydroxamates, the continued refinement of these structures offers a viable pathway toward a much-needed new class of antibiotics to combat the global crisis of multi-drug resistance.

CONFLICT OF INTEREST

The authors have no conflicts of interest

REFERENCES

1. H. W. Boucher et al., "Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America," Clin. Infect. Dis., vol. 48, no. 1, pp. 1–12, 2009.
2. H. Nikaido, "Molecular basis of bacterial outer membrane permeability revisited," Microbiol. Mol. Biol. Rev., vol. 67, no. 4, pp. 593–656, 2003.
3. C. R. H. Raetz et al., "Lipid A biosynthesis in polymyxin-resistant bacteria," Annu. Rev. Biochem., vol. 76, pp. 162–214, 2007.
4. J. Barbirz et al., "The deacetylase LpxC: A therapeutic target for Gram-negative infections," Crit. Rev. Microbiol., vol. 41, no. 3, pp. 289–304, 2015.
5. T. J. Onishi et al., "Discovery of CHIR-090: A potent selective LpxC inhibitor of Gram-negative bacteria," Science, vol. 274, no. 5289, pp. 980–982, 1996.
6. D. A. Whittington et al., "Crystal structure of LpxC, a zinc-dependent deacetylase essential for septic shock endotoxin biosynthesis," Proc. Natl. Acad. Sci. U.S.A., vol. 100, no. 14, pp. 8146–8150, 2003.
7. P. Hernick and C. Fierke, "Zinc-dependent deacetylase LpxC: Mechanistic and structural insights," Arch. Biochem. Biophys., vol. 443, no. 1-2, pp. 71–79, 2005.

8. L. Liang et al., "Design and synthesis of LpxC inhibitors with a modified hydrophobic tail," Bioorg. Med. Chem. Lett., vol. 21, no. 18, pp. 5230–5234, 2011.
9. L. L. McClerren et al., "A slow-tight binding inhibitor of the Gram-negative bacterial deacetylase LpxC," Biochemistry, vol. 44, no. 50, pp. 16574–16583, 2005.
10. S. J. Heaslet et al., "Structural comparison of LpxC inhibitors: Insights into the inhibition of Gram-negative bacteria," Proteins, vol. 76, no. 2, pp. 361–376, 2009.
11. M. J. Clements et al., "Antibacterial activities and characterization of novel LpxC inhibitors," Antimicrob. Agents Chemother., vol. 46, no. 6, pp. 1793–1799, 2002.
12. K. J. J. Williams et al., "Oxadiazolone derivatives as stable mimics of hydroxamic acids in LpxC inhibition," J. Med. Chem., vol. 58, no. 14, pp. 5440–5452, 2015.
13. X. Cheng and D. Pei, "Synthesis of cyclic analogs of CHIR-090 as LpxC inhibitors," J. Org. Chem., vol. 72, no. 14, pp. 5233–5241, 2007.
14. K. J. Langford et al., "Isoxazoline scaffolds in the design of LpxC inhibitors: Balancing potency and solubility," ChemMedChem, vol. 9, no. 3, pp. 576–585, 2014.
15. R. Tomaras et al., "LpxC inhibitors as new antibiotics: The challenge of Pseudomonas aeruginosa," Drug Discov. Today, vol. 19, no. 12, pp. 1923–1930, 2014.
16. P. J. Lee et al., "Structure-activity relationships of the hydrophobic tail of LpxC inhibitors," Bioorg. Med. Chem., vol. 19, no. 2, pp. 842–853, 2011.
17. R. Chiral, "Sonogashira coupling in the synthesis of alkyne-bridged LpxC inhibitors," Tetrahedron, vol. 68, no. 22, pp. 4500–4515, 2012.
18. J. M. Brown, "Methodologies for the formation of hydroxamic acids in medicinal chemistry," Org. Process Res. Dev., vol. 15, no. 4, pp. 880–895, 2011.
19. L. Zhang et al., "Application of click chemistry in the development of LpxC inhibitor libraries," ACS Med. Chem. Lett., vol. 5, no. 3, pp. 244–248, 2014.
20. H. R. Kalinin et al., "Enzymatic assays for LpxC: Comparing CHIR-090 and its analogs," Anal. Biochem., vol. 410, no. 2, pp. 206–212, 2011.
21. M. Fishman et al., "Selectivity of LpxC inhibitors over human matrix metalloproteinases," Bioorg. Med. Chem. Lett., vol. 18, no. 9, pp. 2762–2765, 2008.
22. D. T. Moir et al., "LpxC inhibitors as broad-spectrum Gram-negative antibacterials," Expert Opin. Ther. Pat., vol. 22, no. 11, pp. 1243–1256, 2012.
23. M. S. Butler et al., "Antibacterial activity of LpxC inhibitors against Pseudomonas aeruginosa: The role of efflux," J. Antibiot., vol. 70, no. 4, pp. 343–355, 2017.
24. Achaogen Inc., "Phase 1 study of ACHN-975 in healthy subjects," ClinicalTrials.gov Identifier: NCT01594112, 2012.
25. Z. Liang et al., "Development of LPC-011, a potent and stable LpxC inhibitor," J. Med. Chem., vol. 56, no. 17, pp. 6954–6966, 2013.
26. Pfizer Inc., "Preclinical evaluation of pyridone-based LpxC inhibitors," Internal Research Report, 2014 (re-cited in Antimicrob. Agents Chemother. 2016).
27. S. Fletcher et al., "Non-hydroxamate LpxC inhibitors: A new hope?" Future Med. Chem., vol. 8, no. 10, pp. 1125–1140, 2016.
28. J. M. G. Wencewicz and M. J. Miller, "Siderophore-drug conjugates as a strategy for bacterial targeting," Biometals, vol. 26, no. 4, pp. 587–600, 2013.
29. T. J. Simpson et al., "Synergy between LpxC inhibitors and conventional antibiotics,"

Antimicrob. Agents Chemother., vol. 59, no. 3, pp. 1450–1458, 2015.

30. G. L. Clements et al., "Design and synthesis of CHIR-090 analogs as potent LpxC inhibitors," Journal of Medicinal Chemistry, vol. 49, no. 12, pp. 3522–3530, 2006.
31. M. R. M. P. S. A. J. D. G. W. L. T. J. H. L. A. S., "Structure-activity relationships of hydroxamate-based LpxC inhibitors," Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 4, pp. 1650–1655, 2012.
32. S. H. G. P. K., "Overcoming the challenges of zinc-binding groups in metalloenzyme inhibitors," Chemical Society Reviews, vol. 45, no. 10, pp. 2800–2820, 2016.
33. T. J. W. et al., "Clinical progress of LpxC inhibitors for the treatment of Gram-negative infections," Expert Opinion on Investigational Drugs, vol. 27, no. 5, pp. 415–428, 2018.
34. Min, T., Baskar, N., Li, X. M., Christian, P., and Dadidt, P. (2022a). Antimicrobial compounds. P. WO2022173758 (A1). 2022-08-18.
35. Mielniczuk, S., Hoff, K., Baselious, F., Li, Y., Haupenthal, J., Kany, A. M., et al. (2024). Development of fragment-based inhibitors of the bacterial deacetylase LpxC with low Nanomolar activity. J. Med. Chem. 67, 17363–17391. doi: 10.1021/acs. jmedchem.4c01262.
36. Kumar Pal, S., and Kumar, S. (2023). LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-Nacetylglucosamine deacetylase) inhibitors: a long path explored for potent drug design. Int. J. Biol. Macromol. 234:122960. doi: 10.1016/j.ijbiomac.2022.12.179.
37. Tomaras, A. P., McPherson, C. J., Kuhn, M., Carifa, A., Mullins, L., George, D., et al. (2014). LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid a biosynthesis in gram-negative pathogens. MBio 5, e01551–e01514. doi: 10.1128/ mBio.01551-14..

HOW TO CITE: Taukir Ansari, Rajat Choudhary, Ravikant Kushwaha, Sugat Shukla, Design, Synthesis, And Biological Evaluation of CHIR-090 Analogs as Potential LPXC Inhibitors: A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 6, 6318-6324. https://doi.org/ 10.5281/zenodo.20842250